Cure Today: Antiangiogenic gene therapy

A novel antiangiogenic gene therapy, added to another antiangiogenic agent, Avastin (bevacizumab), led to significantly better overall survival (OS) in recurrent glioblastoma multiforme (GBM) compared with historical patients treated with Avastin alone, a small phase 2 trial showed.

Read the full story at Cure Today



Share This Article!
Article categories: In the News